My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

145.23 -0.43 (-0.30%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
NASDAQ:NBIX qualifies as a high growth stock and is consolidating.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—A High-Growth Stock Gearing Up for Its Next Upward Move. 
Via Chartmill
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
Why NEUROCRINE BIOSCIENCES INC ( NASDAQ:NBIX ) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
Analyst Expectations for Neurocrine Biosciences's Future
 
Via Benzinga
GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in... 
Via Benzinga
What's Going On With Neurocrine Biosciences Stock Today?
Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due... 
Via Benzinga
Analyst Ratings for Neurocrine Biosciences
 
Via Benzinga
Analyst Ratings for Neurocrine Biosciences
 
Via Benzinga
Earnings Outlook For Neurocrine Biosciences
 
Via Benzinga
What To Know About BMO Capital's Upgrade of Neurocrine Biosciences
 
Via Benzinga
Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High?
The company is working on a treatment for a disorder than can cause children to begin puberty early. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning
The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated  
Via Benzinga
Confidence Boost From Ingrezza Sales: Analyst Upgrades Neurocrine Biosciences
BMO Capital Markets has upgraded Neurocrine Biosciences Inc (NASDAQ: NBIX) from Underperform to Market Perform, with a price target of $96,  
Via Benzinga
Expert Ratings for Neurocrine Biosciences
 
Via Benzinga
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences
 
Via Benzinga
Neurocrine Biosciences's Return On Capital Employed Overview
 
Via Benzinga
Neurocrine Biosciences Clocks 35% Revenue Growth In Q1, Misses On Bottom-Line Performance
 
Via Benzinga
Neurocrine Biosciences: Q1 Earnings Insights
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 6, 2023
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
 
Via Benzinga
Neurocrine Biosciences's Earnings: A Preview
 
Via Benzinga
What 15 Analyst Ratings Have To Say About Neurocrine Biosciences
 
Via Benzinga
Expert Ratings for Neurocrine Biosciences
 
Via Benzinga
3 Pharma Stocks That Could See a Surge in Demand in 2023
These pharma stocks to buy are poised for long-term growth in the trillion-dollar biotechnology space, offering tremendous upside ahead 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For March 30, 2023
 
Via Benzinga
3 Growth Stocks That Could Disrupt the Healthcare Industry
These healthcare growth stocks will continue to provide steady and consistent returns, rewarding smart investors over time. 
Via InvestorPlace
Analyst Expectations for Neurocrine Biosciences's Future
 
Via Benzinga
Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets
Neurocrine also topped fourth-quarter revenue expectations on Monday. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2023
 
Via Benzinga
Sentia Medical Sciences and Neurocrine Biosciences Extend Research Collaboration to Discover Novel CRF Peptides
From Sentia Medical Sciences, Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.